Does the media refer more to PRAX or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Roivant Sciences and 8 mentions for Praxis Precision Medicines. Roivant Sciences' average media sentiment score of 0.64 beat Praxis Precision Medicines' score of 0.24 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or INSM?

In the previous week, Insmed had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Insmed and 8 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.24 beat Insmed's score of 0.05 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INCY or PRAX?

In the previous week, Incyte and Incyte both had 8 articles in the media. Incyte's average media sentiment score of 0.40 beat Praxis Precision Medicines' score of 0.24 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BNTX or PRAX?

In the previous week, BioNTech had 14 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 22 mentions for BioNTech and 8 mentions for Praxis Precision Medicines. BioNTech's average media sentiment score of 0.46 beat Praxis Precision Medicines' score of 0.24 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 9 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GMAB or PRAX?

In the previous week, Genmab A/S had 15 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 23 mentions for Genmab A/S and 8 mentions for Praxis Precision Medicines. Genmab A/S's average media sentiment score of 0.25 beat Praxis Precision Medicines' score of 0.24 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 3 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Praxis Precision Medicines (PRAX) Competitors

$263.55 -14.47 (-5.20%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$263.55 0.00 (0.00%)

As of 10/8/2026 07:56 PM Eastern

Compare

PRAX vs. ROIV, INSM, INCY, BNTX, and GMAB

Should you buy Praxis Precision Medicines stock or one of its competitors? Praxis Precision Medicines's main competitors and comparable companies include Roivant Sciences (ROIV), Insmed (INSM), Incyte (INCY), BioNTech (BNTX), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Praxis Precision Medicines compare to Roivant Sciences?

Praxis Precision Medicines (NASDAQ:PRAX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Praxis Precision Medicines currently has a consensus target price of $613.26, indicating a potential upside of 132.69%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 33.40%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Roivant Sciences had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Roivant Sciences and 8 mentions for Praxis Precision Medicines. Roivant Sciences' average media sentiment score of 0.64 beat Praxis Precision Medicines' score of 0.24 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has lower revenue, but higher earnings than Praxis Precision Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	860.62	-$303.27M	-$12.93	N/A
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Insmed?

Praxis Precision Medicines (NASDAQ:PRAX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Praxis Precision Medicines has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Praxis Precision Medicines has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	860.62	-$303.27M	-$12.93	N/A
Insmed	$606.42M	36.18	-$1.28B	-$4.11	N/A

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Insmed had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Insmed and 8 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.24 beat Insmed's score of 0.05 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Praxis Precision Medicines' return on equity of -34.15% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Insmed	-76.94%	-123.94%	-44.30%

Praxis Precision Medicines presently has a consensus target price of $613.26, suggesting a potential upside of 132.69%. Insmed has a consensus target price of $200.57, suggesting a potential upside of 99.61%. Given Praxis Precision Medicines' higher probable upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Praxis Precision Medicines beats Insmed on 12 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Incyte?

Incyte (NASDAQ:INCY) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Incyte has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market.

Incyte has a net margin of 27.71% compared to Praxis Precision Medicines' net margin of 0.00%. Incyte's return on equity of 29.93% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Incyte has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.45	$1.29B	$7.85	14.36
Praxis Precision Medicines	$8.55M	860.62	-$303.27M	-$12.93	N/A

Incyte presently has a consensus target price of $127.70, suggesting a potential upside of 13.26%. Praxis Precision Medicines has a consensus target price of $613.26, suggesting a potential upside of 132.69%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

97.0% of Incyte shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Incyte and Incyte both had 8 articles in the media. Incyte's average media sentiment score of 0.40 beat Praxis Precision Medicines' score of 0.24 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Incyte beats Praxis Precision Medicines on 10 of the 16 factors compared between the two stocks.

How does Praxis Precision Medicines compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Praxis Precision Medicines has lower revenue, but higher earnings than BioNTech. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.17	-$1.29B	-$7.83	N/A
Praxis Precision Medicines	$8.55M	860.62	-$303.27M	-$12.93	N/A

BioNTech has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

BioNTech currently has a consensus price target of $125.69, suggesting a potential upside of 36.53%. Praxis Precision Medicines has a consensus price target of $613.26, suggesting a potential upside of 132.69%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

In the previous week, BioNTech had 14 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 22 mentions for BioNTech and 8 mentions for Praxis Precision Medicines. BioNTech's average media sentiment score of 0.46 beat Praxis Precision Medicines' score of 0.24 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of BioNTech shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Praxis Precision Medicines beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Genmab A/S has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Praxis Precision Medicines' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Genmab A/S has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	6.05	$963M	$1.27	28.39
Praxis Precision Medicines	$8.55M	860.62	-$303.27M	-$12.93	N/A

In the previous week, Genmab A/S had 15 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 23 mentions for Genmab A/S and 8 mentions for Praxis Precision Medicines. Genmab A/S's average media sentiment score of 0.25 beat Praxis Precision Medicines' score of 0.24 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S currently has a consensus target price of $42.50, indicating a potential upside of 17.89%. Praxis Precision Medicines has a consensus target price of $613.26, indicating a potential upside of 132.69%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRAX vs. The Competition

Export

Metric	Praxis Precision Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.76B	$3.87B	$7.20B	$13.40B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-20.38	13.89	274.65	25.98
Price / Sales	860.62	1,200.11	577.32	85.22
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	7.56	16.11	10.81	6.27
Net Income	-$303.27M	-$22.69M	$3.50B	$382.01M
7 Day Performance	-10.82%	-2.88%	-1.83%	-1.60%
1 Month Performance	-23.68%	-11.16%	-6.34%	-4.63%
1 Year Performance	381.28%	8.32%	3.08%	-0.95%

Praxis Precision Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRAX Praxis Precision Medicines	2.5982 of 5 stars	$263.55 -5.2%	$613.26 +132.7%	+385.4%	$7.76B	$8.55M	N/A	168	Analyst Forecast
ROIV Roivant Sciences	3.2274 of 5 stars	$36.98 +3.3%	$45.64 +23.4%	+113.4%	$25.86B	$8.26M	N/A	721
INSM Insmed	3.6283 of 5 stars	$117.67 -0.1%	$201.87 +71.6%	-37.9%	$25.73B	$606.42M	N/A	1,664	Analyst Forecast
INCY Incyte	3.7299 of 5 stars	$124.82 +0.8%	$124.80 0.0%	+32.1%	$25.11B	$5.14B	15.90	2,844	Analyst Forecast
BNTX BioNTech	4.0736 of 5 stars	$99.08 +0.6%	$126.00 +27.2%	-13.4%	$24.91B	$3.25B	N/A	7,807	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRAX) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ROIV, INSM, INCY, BNTX, and GMAB

How does Praxis Precision Medicines compare to Roivant Sciences?

Summary

How does Praxis Precision Medicines compare to Insmed?

Summary

How does Praxis Precision Medicines compare to Incyte?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Summary

How does Praxis Precision Medicines compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ROIV, INSM, INCY, BNTX, and GMAB

How does Praxis Precision Medicines compare to Roivant Sciences?

Do analysts prefer PRAX or ROIV?

Does the media refer more to PRAX or ROIV?

Which has higher valuation and earnings, PRAX or ROIV?

Is PRAX or ROIV more profitable?

Do insiders and institutionals hold more shares of PRAX or ROIV?

Which has more risk & volatility, PRAX or ROIV?

Summary

How does Praxis Precision Medicines compare to Insmed?

Which has more risk & volatility, PRAX or INSM?

Which has higher earnings & valuation, PRAX or INSM?

Do insiders and institutionals hold more shares of PRAX or INSM?

Does the media favor PRAX or INSM?

Is PRAX or INSM more profitable?

Do analysts rate PRAX or INSM?

Summary

How does Praxis Precision Medicines compare to Incyte?

Which has more risk & volatility, INCY or PRAX?

Is INCY or PRAX more profitable?

Which has stronger valuation and earnings, INCY or PRAX?

Do analysts rate INCY or PRAX?

Do institutionals & insiders have more ownership in INCY or PRAX?

Does the media prefer INCY or PRAX?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Which has higher earnings & valuation, BNTX or PRAX?

Which has more risk and volatility, BNTX or PRAX?

Is BNTX or PRAX more profitable?

Do analysts prefer BNTX or PRAX?

Does the media prefer BNTX or PRAX?

Do institutionals & insiders have more ownership in BNTX or PRAX?

Summary

How does Praxis Precision Medicines compare to Genmab A/S?

Which has more volatility and risk, GMAB or PRAX?

Is GMAB or PRAX more profitable?

Which has stronger valuation & earnings, GMAB or PRAX?

Does the media refer more to GMAB or PRAX?

Do analysts recommend GMAB or PRAX?

Do institutionals and insiders have more ownership in GMAB or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools